“It’s truly one of the most versatile ingredients we have,” explains board-certified dermatologist Dhaval Bhanusali, M.D.

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

As the seasons change, your skin-care routine might need to change too. Prevent and soothe dry, irritated winter skin with ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.